Cold season is here and sometimes the flu vaccine and washing our hands just aren’t enough to keep colds at bay. If you do get sick, make sure the over-the-counter (OTC) medication you take doesn’t damage your liver while it’s relieving your cold symptoms
Acetaminophen (brand name Tylenol) is the most popular painkiller in the United States. (In other parts of the world it is known as Paracetamol.) Not only is it found in the 8 billion acetaminophen pills Americans take each year to reduce aches and pains, it’s also found in cough and congestion medications. When we have hepatitis B, we need to be careful we don’t unintentionally overdose when we take acetaminophen pills and cough or sinus medications. Continue reading "It’s Flu Season: Protect Your Liver from Unintentional Acetaminophen (Tylenol) Overdose"→
With the cost of health care and prescription drugs soaring, it’s important to choose health insurance carefully when you take hepatitis B medications and need frequent check-ups and lab tests.
In the next two months, Medicare recipients, people who get insurance through their jobs and consumers buying coverage through the Affordable Care Act (Obamacare) will be selecting insurance plans during open enrollment.
If you take antivirals or interferon and have frequent lab tests and doctor visits, it’s important that you select the plan that:
Has your specialist or primary care doctor and lab in its network,
And offers the lowest copay for the drugs you need.
Telling someone you have hepatitis B is almost always followed by the question, “how did you get it?”
The question can feel like an invasion of privacy or an indictment. Behind the question lurks a desire for reassurance that hepatitis B won’t happen to them, but of course it can. And that’s why we should answer and tell our story.
The day my daughter started kindergarten, her teacher asked that she be transferred to another classroom. She thought my daughter posed a health threat to a classmate who was recovering from leukemia.
Our doctor had disclosed my daughter’s chronic hepatitis B infection on her school health form. I thought the school nurse would know my daughter posed no risk to students, who were nearly all immunized against hepatitis B and supervised by teachers trained in universal precautions.
I was wrong on many counts. The school nurse went along with the teacher’s recommendation. After heated discussions with the school principal that included providing copies of medical reports and civil rights laws, my daughter remained in the classroom and the school’s staff received training on universal precautions.
That happened 16 years ago. The Americans with Disabilities Act (ADA) had been enacted 10 years earlier and policy makers, health officials and the courts were still working out exactly how the landmark law would protect people with blood-borne infections such as HIV and hepatitis B and C.
In celebration of Asian Pacific Heritage Month, Dr. moon Chen, Principal Investigator for the Asian American Network for Cancer Awareness Research and Training (AANCART) and UC Davis professor, reflects on the unnecessary cancer burden in Asian American and Pacific Islanders, including the burden of hepatitis B related liver cancer. Continue reading "May is Asian Pacific American Heritage Month"→
The World Health Organization (WHO) will release their first management guidelines for hepatitis B virus (HBV) by the end of 2014. For the first time, the guidelines will be geared towards resource-constrained countries, where the disease burden is high but resources are lacking. The new guidelines will be particularly welcome in African nations, where the incidence of viral hepatitis is increasing.
The overall scope of the World Health Organization’s new management guidelines for hepatitis B will include prevention, screening, and treatment of chronic hepatitis B and will be geared towards resource-constrained countries. Thus, WHO’s guidelines will be valuable for countries where the disease burden is high but resources are lacking.
Yet, only two of the African member states that responded to the WHO Survey have a written national strategy to prevent and control viral hepatitis.
In Ghana, where the incidence of viral hepatitis is increasing, the sero-prevalence rate is high among blood donors (6.7%), pregnant women (6.5%) and school
aged children (15.6%), according to Mr. Theobald Owusu-Ansah, president of the Theobald Hepatitis B Foundation and the Hepatitis B Coalition in Ghana.
Compounding the lack of public health plans and national investment are factors common in many low-resource countries: limited awareness of hepatitis B among the public and providers, poor access to care, expensive therapies, and few liver specialists.
Global agencies are beginning to recognize the urgency of the situation. In addition to the WHO, the World Health Assembly is taking steps to combat the growing crisis. The Assembly adopted a second resolution on viral hepatitis in May 2014 that advises governments on how to prioritize and coordinate public health efforts.
But governments cannot tackle these problems alone, Mr. Owusu-Ansah believes. He urges governments to partner with commercial and nonprofit organizations to mobilize much-needed expertise and resources.